AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develop treatments for rare, chronic, and infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company uses boron chemistry for its research and development initiatives. AN2 was incorporated in 2017 and is headquartered in Menlo Park, CA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$2.85 | A | |
$8.18 | A | |
$23.45 | A |